EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy

Davide Bindellini iD, Robin Michelet iD, Linda B S Aulin iD, Johanna Melin iD, Uta Neumann iD, Oliver Blankenstein iD, Wilhelm Huisinga iD, Martin J Whitaker iD, Richard Ross iD, Charlotte Kloft

Journal of Pharmacokinetics and Pharmacodynamics · 2024

DOI: 10.1007/s10928-024-09934-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacokinetics and Pharmacodynamics, 2024. Verfasst von Davide Bindellini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Hydrocortisone, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System, Adrenocorticotropic Hormone. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Freie Universität Berlin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Congenital adrenal hyperplasia (CAH) is characterized by impaired adrenal cortisol production. Hydrocortisone (synthetic cortisol) is the drug-of-choice for cortisol replacement therapy, aiming to mimic physiological cortisol circadian rhythm. The hypothalamic-pituitary-adrenal (HPA) axis controls cortisol production through the pituitary adrenocorticotropic hormone (ACTH) and feedback mechanisms. The aim of this study was to quantify key mechanisms involved in the HPA axis activity regulation and their interaction with hydrocortisone therapy. Data from 30 healthy volunteers was leveraged: Endogenous ACTH and cortisol concentrations without any intervention as well as cortisol concentrations measured after dexamethasone suppression and single dose administration of (i) 0.5–10 mg hydrocortisone as granules, (ii) 20 mg hydrocortisone as granules and intravenous bolus. A stepwise model development workflow was used: A newly developed model for endogenous ACTH and cortisol was merged with a refined hydrocortisone pharmacokinetic model. The joint model was used to simulate ACTH and cortisol trajectories in CAH patients with varying degrees of enzyme deficiency, with or without hydrocortisone administration, and healthy individuals. Time-dependent ACTH-driven endogenous cortisol production and cortisol-mediated feedback inhibition of ACTH secretion processes were quantified and implemented in the model. Comparison of simulated ACTH and cortisol trajectories between CAH patients and healthy individuals showed the importance of administering hydrocortisone before morning ACTH secretion peak time to suppress ACTH overproduction observed in untreated CAH patients. The developed framework allowed to gain insights on the physiological mechanisms of the HPA axis regulation, its perturbations in CAH and interaction with hydrocortisone administration, paving the way towards cortisol replacement therapy optimization. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrocortisoneHypothalamo-Hypophyseal SystemPituitary-Adrenal SystemAdrenocorticotropic HormoneHormone Replacement TherapyDexamethasoneModels, BiologicalHumansAdultMaleFemaleAdrenal Hyperplasia, CongenitalYoung AdultCircadian RhythmMiddle AgedHealthy Volunteers

Stichwörter der Autor:innen

ACTHCircadian rhythmCongenital adrenal hyperplasiaCortisolCortisol replacement therapyModeling

Substanzen

HydrocortisoneAdrenocorticotropic HormoneDexamethasone

Autor:innen und Institutionen

  • Dept. of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
  • Graduate Research Training program PharMetrX, Berlin, Germany.
  • Dept. of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany. robin.michelet@fu-berlin.de.
  • Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Labor Berlin, Charité Vivantes GmbH, Berlin, Germany.
  • Institute of Mathematics, University of Potsdam, Potsdam, Germany.

ORCID-Profile: Davide Bindellini, Robin Michelet, Linda B S Aulin, Johanna Melin, Uta Neumann, Oliver Blankenstein, Wilhelm Huisinga, Martin J Whitaker, Richard Ross

Förderung

  • Freie Universität Berlin

Zitieren

APA

Bindellini, D., Michelet, R., Aulin, L. B. S., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Whitaker, M. J., Ross, R., & Kloft, C. (2024). A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy. Journal of Pharmacokinetics and Pharmacodynamics. https://doi.org/10.1007/s10928-024-09934-7

Vancouver

Bindellini D, Michelet R, Aulin LBS, Melin J, Neumann U, Blankenstein O, et al. A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy. Journal of Pharmacokinetics and Pharmacodynamics. 2024. doi:10.1007/s10928-024-09934-7

BibTeX
@article{Bindellini2024,
  author = {Bindellini, Davide and Michelet, Robin and Aulin, Linda B S and Melin, Johanna and Neumann, Uta and Blankenstein, Oliver and Huisinga, Wilhelm and Whitaker, Martin J and Ross, Richard and Kloft, Charlotte},
  title = {A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy},
  journal = {Journal of Pharmacokinetics and Pharmacodynamics},
  year = {2024},
  doi = {10.1007/s10928-024-09934-7}
}
Kostenlos starten →